A Pharmacogenomic Landscape in Human Liver Cancers.

Animals Antineoplastic Agents / pharmacology Asian People / genetics Biomarkers, Tumor / genetics Carcinoma, Hepatocellular / drug therapy Cell Line, Tumor Clinical Decision-Making Databases, Genetic Drug Resistance, Neoplasm / genetics Female Genetic Heterogeneity Genetic Predisposition to Disease High-Throughput Nucleotide Sequencing Humans Liver Neoplasms / drug therapy Male Mice, Inbred BALB C Mice, Inbred NOD Mice, Nude Mice, SCID Patient Selection Pharmacogenomic Testing Pharmacogenomic Variants Phenotype Precision Medicine Protein Kinase Inhibitors / pharmacology Sorafenib / pharmacology Xenograft Model Antitumor Assays
liver cancer patient-derived cancer models pharmacogenomics sorafenib

Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
12 08 2019
Historique:
received: 27 11 2018
revised: 17 05 2019
accepted: 01 07 2019
pubmed: 6 8 2019
medline: 21 4 2020
entrez: 6 8 2019
Statut: ppublish

Résumé

Liver cancers are highly heterogeneous with poor prognosis and drug response. A better understanding between genetic alterations and drug responses would facilitate precision treatment for liver cancers. To characterize the landscape of pharmacogenomic interactions in liver cancers, we developed a protocol to establish human liver cancer cell models at a success rate of around 50% and generated the Liver Cancer Model Repository (LIMORE) with 81 cell models. LIMORE represented genomic and transcriptomic heterogeneity of primary cancers. Interrogation of the pharmacogenomic landscape of LIMORE discovered unexplored gene-drug associations, including synthetic lethalities to prevalent alterations in liver cancers. Moreover, predictive biomarker candidates were suggested for the selection of sorafenib-responding patients. LIMORE provides a rich resource facilitating drug discovery in liver cancers.

Identifiants

DOI: 10.1016/j.ccell.2019.07.001 PMID: 31378681 PMC: PMC7505724
pubmed: 31378681
pii: S1535-6108(19)30328-9
doi: 10.1016/j.ccell.2019.07.001
pmc: PMC7505724
mid: NIHMS1622926
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Biomarkers, Tumor 0
Protein Kinase Inhibitors 0
Sorafenib 9ZOQ3TZI87

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-193.e11

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Hepatology. 2016 Jan;63(1):173-84
pubmed: 26403645
Oncogene. 2004 Nov 4;23(52):8520-6
pubmed: 15378020
J Hepatol. 2018 Jun;68(6):1203-1213
pubmed: 29525529
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Cell. 2014 Sep 25;159(1):176-187
pubmed: 25201530
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Nature. 2017 Jul 6;547(7661):99-103
pubmed: 28459430
Cell. 2018 Apr 5;173(2):515-528.e17
pubmed: 29625057
Cancer Cell. 2008 Dec 9;14(6):471-84
pubmed: 19061838
Cell Stem Cell. 2017 Jan 5;20(1):41-55
pubmed: 27840021
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Cell. 2018 May 3;173(4):864-878.e29
pubmed: 29681454
Nature. 2015 Apr 16;520(7547):307-11
pubmed: 25877200
Nat Methods. 2016 Jun;13(6):521-7
pubmed: 27135972
Nat Rev Genet. 2015 Jul;16(7):373-4
pubmed: 26077369
Genome Res. 2012 Dec;22(12):2315-27
pubmed: 23033341
J Hepatol. 2012 Jun;56(6):1343-50
pubmed: 22322234
Hepatology. 2016 Oct;64(4):1105-20
pubmed: 27177758
Gastroenterology. 2019 Sep;157(3):760-776
pubmed: 31063779
Cancer Res. 2008 Aug 15;68(16):6779-88
pubmed: 18701503
Dig Liver Dis. 2013 Mar;45(3):251-7
pubmed: 23266194
Am J Pathol. 2000 Sep;157(3):763-70
pubmed: 10980116
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
Nature. 2007 Apr 5;446(7136):676-9
pubmed: 17377531
Clin Cancer Res. 2009 Dec 15;15(24):7529-7537
pubmed: 20008853
Nat Genet. 2016 May;48(5):500-9
pubmed: 27064257
J Clin Invest. 2009 Jun;119(6):1727-40
pubmed: 19451690
Nat Chem Biol. 2013 Nov;9(11):708-14
pubmed: 24013279
Gastroenterology. 2012 Apr;142(4):957-966.e12
pubmed: 22202459
Sci Rep. 2016 Jun 07;6:27411
pubmed: 27273737
Bioinformatics. 2011 Jan 15;27(2):268-9
pubmed: 21081509
Cancer Res. 2009 Sep 15;69(18):7385-92
pubmed: 19723656
Cell. 2015 Jan 15;160(1-2):324-38
pubmed: 25557080
Nat Chem Biol. 2014 Sep;10(9):768-773
pubmed: 25064833
Liver Int. 2011 Nov;31(10):1494-504
pubmed: 21955977
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Cell. 2013 Aug 29;154(5):1151-1161
pubmed: 23993102
PLoS One. 2012;7(9):e45268
pubmed: 23028896
Cancer Res. 2008 Feb 1;68(3):664-73
pubmed: 18245465
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
Cancer Res. 2014 Jun 15;74(12):3238-47
pubmed: 24755471
J Hepatol. 2016 Apr;64(1 Suppl):S84-S101
pubmed: 27084040
Stem Cell Reports. 2017 Dec 12;9(6):1813-1824
pubmed: 29173899
Cell Rep. 2018 Jul 31;24(5):1363-1376
pubmed: 30067989
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Lancet Oncol. 2012 Aug;13(8):817-26
pubmed: 22738799
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Curr Opin Genet Dev. 2014 Feb;24:114-9
pubmed: 24607840
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Am J Pathol. 2012 Feb;180(2):599-607
pubmed: 22189618
J Hepatol. 2017 Nov;67(5):896-897
pubmed: 28807831
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Genome Res. 2013 Sep;23(9):1422-33
pubmed: 23788652
Mol Cell Biol. 2000 Sep;20(18):6882-90
pubmed: 10958684
Science. 2014 Dec 19;346(6216):1480-6
pubmed: 25394791
Hepatology. 2014 Dec;60(6):1972-82
pubmed: 24798001
Nat Genet. 2012 May 27;44(7):765-9
pubmed: 22634754
Curr Opin Genet Dev. 2014 Feb;24:68-73
pubmed: 24657539
Cell. 2018 Jan 11;172(1-2):373-386.e10
pubmed: 29224780
Nat Genet. 2015 May;47(5):505-511
pubmed: 25822088
Oncotarget. 2015 Aug 28;6(25):20959-63
pubmed: 26087185
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
Cell Chem Biol. 2017 Sep 21;24(9):1066-1074
pubmed: 28736238
Nature. 2012 Mar 28;483(7391):570-5
pubmed: 22460902
Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58
pubmed: 20628345
Cancer Discov. 2017 May;7(5):462-477
pubmed: 28331002
Cancer Cell. 2015 Mar 9;27(3):382-96
pubmed: 25759023
Cancer Discov. 2015 Nov;5(11):1210-23
pubmed: 26482930
Cancer Res. 2011 Nov 15;71(22):6940-7
pubmed: 21940749
Nat Commun. 2017 Feb 10;8:14262
pubmed: 28186126
Nat Med. 2017 Dec;23(12):1424-1435
pubmed: 29131160
Science. 2018 Feb 23;359(6378):920-926
pubmed: 29472484
Liver Int. 2015 Mar;35(3):999-1009
pubmed: 24461059
Mol Cancer Res. 2016 Jan;14(1):3-13
pubmed: 26248648
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505

Auteurs

Zhixin Qiu (Z)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Hong Li (H)

CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Zhengtao Zhang (Z)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Zhenfeng Zhu (Z)

Department of Minimally Invasive Therapy, Collaborative Innovation Center for Cancer Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Sheng He (S)

CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China; School of Life Science and Technology, Shanghai Tech University, Shanghai 201210, China.

Xujun Wang (X)

SJTU-Yale Joint Center for Biostatistics, Department of Bioinformatics and Biostatistics, Shanghai Jiaotong University, Shanghai 200240, China.

Pengcheng Wang (P)

Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Shanghai 200032, China.

Jianjie Qin (J)

Liver Transplantation Center, Key Laboratory of Living Donor Liver Transplantation of Ministry of Public Health, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.

Liping Zhuang (L)

Department of Minimally Invasive Therapy, Collaborative Innovation Center for Cancer Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Wei Wang (W)

Shanghai ChemPartner Co., Ltd., Shanghai 201203, China.

Fubo Xie (F)

Shanghai ChemPartner Co., Ltd., Shanghai 201203, China.

Ying Gu (Y)

Shanghai ChemPartner Co., Ltd., Shanghai 201203, China.

Keke Zou (K)

CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Chao Li (C)

CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Chun Li (C)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Chenhua Wang (C)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Jin Cen (J)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Xiaotao Chen (X)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Yajing Shu (Y)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Zhao Zhang (Z)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Lulu Sun (L)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Lihua Min (L)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

Yong Fu (Y)

Fifth Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China.

Xiaowu Huang (X)

Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Shanghai 200032, China.

Hui Lv (H)

SJTU-Yale Joint Center for Biostatistics, Department of Bioinformatics and Biostatistics, Shanghai Jiaotong University, Shanghai 200240, China.

He Zhou (H)

Shanghai ChemPartner Co., Ltd., Shanghai 201203, China.

Yuan Ji (Y)

Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Zhigang Zhang (Z)

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Zhiqiang Meng (Z)

Department of Minimally Invasive Therapy, Collaborative Innovation Center for Cancer Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Xiaolei Shi (X)

Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 211166, China. Electronic address: njsxl2000@163.com.

Haibin Zhang (H)

Fifth Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China. Electronic address: drzhanghb@163.com.

Yixue Li (Y)

CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China. Electronic address: yxli@sibs.ac.cn.

Lijian Hui (L)

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China; School of Life Science and Technology, Shanghai Tech University, Shanghai 201210, China; Bio-Research Innovation Center Suzhou, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Suzhou, Jiangsu 215121, China. Electronic address: ljhui@sibcb.ac.cn.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Personnes › Asiatiques › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Diagnostic › Prise de décision clinique › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Sciences de l'information › Mémorisation et recherche des informations › Bases de données comme sujet › Bases de données factuelles › Bases de données génétiques › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Hétérogénéité génétique › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Phénomènes génétiques › Génotype › Prédisposition génétique à une maladie › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée BALB C › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée NOD › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris nude › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris SCID › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Administration des services de santé › Gestion des soins aux patients › Sélection de patients › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Services de médecine préventive › Services de diagnostic › Dépistage génétique › Test pharmacogénomique › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Variants pharmacogénomiques › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Phénomènes génétiques › Phénotype › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Professions de santé › Médecine › Médecine clinique › Médecine de précision › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Acides nicotiniques › Nicotinamide › Sorafénib › A Pharmacogenomic Landscape in Human Liver Cancers.
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › A Pharmacogenomic Landscape in Human Liver Cancers.